VYNE Therapeutics Inc.
VYNE | NASDAQ
$28.56
$0.00 (0.00%)
Nov 2, 2026, 1:44 PM ET · Market open
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 | Q3 2024 Sep 30, 2024 | Q2 2024 Jun 30, 2024 | Q1 2024 Mar 31, 2024 | Q4 2023 Dec 31, 2023 | Q3 2023 Sep 30, 2023 | Q2 2023 Jun 30, 2023 | Q1 2023 Mar 31, 2023 | Q4 2022 Dec 31, 2022 | Q3 2022 Sep 30, 2022 | Q2 2022 Jun 30, 2022 | Q1 2022 Mar 31, 2022 | Q4 2021 Dec 31, 2021 | Q3 2021 Sep 30, 2021 | Q2 2021 Jun 30, 2021 | Q1 2021 Mar 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 570K | 86K | 130K | 169K | 69K | 202K | 84K | 121K | 198K | 98K | 76K | 114K | 135K | 99K | 6K | 167K | 126K | 178K | 2.29M | 133K | 295K | 230K |
Cost of Revenue | n/a | 6K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 903K | 28K | 28K | n/a |
Gross Profit | 570K | 80K | 130K | 169K | 69K | 202K | 84K | 121K | 198K | 98K | 76K | 114K | 135K | 99K | 6K | 167K | 126K | 178K | 1.39M | 105K | 267K | 230K |
Operating Income | -29.75M | -3.82M | -5.22M | -7.79M | -7.54M | -9.2M | -12.77M | -13.09M | -10.4M | -7.38M | -6.83M | -6.23M | -10.32M | -5.88M | -7.98M | -9.33M | -8.29M | -8.69M | 12.04M | -10.77M | -9.54M | -9.76M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -26.73M | -3.59M | -4.96M | -7.43M | -5.75M | -8.6M | -12.01M | -12.16M | -9.4M | -6.24M | -6.15M | -6.07M | -10.04M | -5.61M | -7.75M | -9.26M | -8.24M | -8.69M | -12.02M | -14.28M | -10.69M | -10.88M |
Net Income | -26.48M | -3.59M | -4.84M | -7.28M | -5.76M | -8.61M | -12.02M | -12.16M | -9.41M | -6.25M | -6.19M | -6.58M | -10.06M | -5.62M | -9.95M | -9.46M | -8.48M | 4.67M | -11.57M | -21.29M | -19.92M | -20.55M |
Selling & General & Admin | 11.08M | 3.08M | 2.37M | 2.71M | 2.73M | 3.28M | 3.17M | 2.96M | 3.29M | 3.77M | 3.89M | 3.03M | 3.22M | 3.24M | 3.71M | 3.95M | 4.31M | 4.42M | 8.2M | 4.96M | 4.76M | 5.73M |
Research & Development | 19.24M | 817K | 2.98M | 5.26M | 4.88M | 6.12M | 9.68M | 10.25M | 7.31M | 3.71M | 3.02M | 3.32M | 7.23M | 2.73M | 4.28M | 5.55M | 4.11M | 4.45M | 5.24M | 5.92M | 5.05M | 4.26M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1 | n/a | -24.09M | n/a | n/a | n/a |
Operating Expenses | 30.32M | 3.9M | 5.35M | 7.96M | 7.61M | 9.4M | 12.85M | 13.21M | 10.59M | 7.48M | 6.91M | 6.35M | 10.45M | 5.97M | 7.99M | 9.5M | 8.41M | 8.87M | -10.66M | 10.87M | 9.81M | 9.99M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 3.47M | 1.07M | 1.06M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 30.32M | 3.9M | 5.35M | 7.96M | 7.61M | 9.4M | 12.85M | 13.21M | 10.59M | 7.48M | 6.91M | 6.35M | 10.45M | 5.97M | 7.99M | 9.5M | 8.41M | 8.87M | -9.75M | 10.9M | 9.84M | 9.99M |
Income Tax Expense | 4K | n/a | 4K | n/a | n/a | n/a | 4K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 13K | n/a | n/a | n/a | -448K | n/a | n/a | n/a |
Shares Outstanding (Basic) | 42.77K | 855.36K | 855.36K | 854.9K | 855.18K | 853.46K | 851.76K | 851.74K | 851.72K | 851.62K | 621K | 65.6K | 65.4K | 65.2K | 59.7K | 64.36K | 64.36K | 61.54K | 59.47K | 57.81K | 57.12K | 54.3K |
Shares Outstanding (Diluted) | 42.77K | 855.36K | 855.36K | 854.9K | 855.18K | 853.46K | 851.76K | 851.74K | 851.72K | 851.62K | 621K | 65.6K | 65.4K | 65.2K | 59.7K | 64.36K | 64.36K | 61.54K | 59.47K | 57.81K | 57.12K | 54.3K |
EPS (Basic) | -619.29 | -4.19 | -5 | -8.50 | -6.50 | -10 | -14 | -14.50 | -11 | -7.50 | -10 | -100.50 | -154 | -86 | -130 | -147 | -131.50 | 76 | -194.50 | -368 | -349 | -378.50 |
EPS (Diluted) | -619.29 | -4.19 | -5 | -8.50 | -6.50 | -10 | -14 | -14.50 | -11 | -7.50 | -10 | -100.50 | -154 | -86 | -130 | -147 | -131.50 | 76 | -194.50 | -368 | -349 | -378.50 |
EBITDA | -29.75M | -3.58M | -4.95M | -7.42M | -5.74M | -8.6M | -12.01M | -12.16M | -8.39M | -6.24M | -6.15M | -6.05M | -9.92M | -5.57M | -7.73M | -9.08M | -8.22M | -8.65M | -11.99M | -10.77M | -9.58M | -9.73M |
EBIT | -29.75M | -3.59M | -4.96M | -7.43M | -5.75M | -8.6M | -12.01M | -12.16M | -9.4M | -6.24M | -6.15M | -6.07M | -10.04M | -5.61M | -7.75M | -9.26M | -8.24M | -8.69M | -12.02M | -10.8M | -9.61M | -9.76M |
Depreciation & Amortization | n/a | 6K | 5K | 6K | 6K | 6K | n/a | n/a | 1M | n/a | n/a | 18K | 122.09K | 41.58K | 18K | 171K | 12K | 44K | 26K | 28K | 28K | 27K |
Add to Watchlist
Select watchlists to add or remove VYNE